Core binding factor

Core Binding Factor (CBF) is a protein complex that plays a crucial role in the regulation of gene expression in both normal cell development and hematopoiesis (the formation of blood cellular components). It is a transcription factor involved in the control of a wide array of genes essential for cell differentiation, especially within the bone marrow and the immune system.

Structure

CBF is a heterodimeric transcription factor, meaning it is composed of two subunits: a CBFα (also known as RUNX1, AML1, PEBP2αB) and a CBFβ. The CBFα subunit binds to DNA through a specific sequence called the core-binding element, while the CBFβ subunit enhances the DNA binding affinity of CBFα. The interaction between these two subunits is critical for the function of CBF in regulating gene expression.

Function

The primary function of CBF is to regulate the expression of genes involved in cell proliferation, differentiation, and apoptosis, particularly in the hematopoietic system. It is essential for the development of all blood cell lineages, including myeloid cells, lymphoid cells, and megakaryocytes. CBF activates or represses its target genes by binding to the core-binding element in their promoters.

Clinical Significance

Alterations in the components of CBF, such as mutations or chromosomal translocations, are associated with various forms of leukemia. The most common alteration is the t(8;21)(q22;q22) translocation, which involves the CBFα subunit and is frequently observed in patients with acute myeloid leukemia (AML). This translocation creates a fusion protein that acts as a dominant-negative inhibitor of CBF, disrupting normal hematopoiesis and leading to leukemia.

Another significant alteration is the inv(16)(p13;q22) or t(16;16)(p13;q22), involving the CBFβ subunit, which is associated with a subtype of AML known as M4Eo. These alterations result in the production of a fusion protein that interferes with the normal function of CBF, contributing to leukemogenesis.

Research and Therapeutic Implications

Understanding the role of CBF in normal hematopoiesis and its dysregulation in leukemia has been crucial for developing targeted therapies. Drugs that can modulate the activity of CBF or its interaction with other proteins offer potential therapeutic strategies for treating leukemias associated with CBF alterations. Ongoing research aims to identify small molecules or peptides that can restore the normal function of CBF or disrupt the function of the fusion proteins resulting from chromosomal translocations.

See Also

• Transcription factor
• Gene expression
• Hematopoiesis
• Leukemia
• Acute myeloid leukemia